Formyl peptide receptor 2 and heart disease

John A Lupisella; Pravin S Shirude; Nicholas R Wurtz; Ricardo A Garcia

doi:10.1016/j.smim.2022.101602

Formyl peptide receptor 2 and heart disease

Semin Immunol. 2022 Jan:59:101602. doi: 10.1016/j.smim.2022.101602. Epub 2022 Mar 8.

Authors

John A Lupisella¹, Pravin S Shirude², Nicholas R Wurtz¹, Ricardo A Garcia³

Affiliations

¹ Department of Cardiovascular and Fibrosis Drug Discovery, Bristol Myers Squibb, Princeton, NJ, USA.
² Biocon Bristol Myers Squibb Research Center, Bangalore, India.
³ Department of Cardiovascular and Fibrosis Drug Discovery, Bristol Myers Squibb, Princeton, NJ, USA; Department of Medicine, University of California San Diego, San Diego, CA, USA. Electronic address: ricardo.garcia@bms.com.

PMID: 35277300
DOI: 10.1016/j.smim.2022.101602

Abstract

Formyl peptide receptor type 2 (FPR2) regulates the initiation and resolution phases of the inflammatory response. In the setting of heart injury and disease, dysregulated inflammation can potentiate maladaptive healing and pathological remodeling of the heart leading to cardiac dysfunction and failure. The potential to regulate and resolve adverse inflammation is postulated to improve outcome in the setting of heart disease. This review covers emerging concepts on the role of FPR2 in heart disease and strategies to activate pro-resolution processes to limit disease progression. We summarize key preclinical studies that support use of FPR2 agonists in heart disease. Finally, we briefly discuss the status of FPR2 agonists under evaluation in the clinic.

Keywords: FPR2, Formyl peptide receptor 2; HF, Heart failure; MI, Myocardial infarction; Resolution.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Heart Diseases*
Humans
Inflammation / pathology
Receptors, Formyl Peptide* / agonists
Receptors, Formyl Peptide* / physiology
Wound Healing

Substances

Receptors, Formyl Peptide
FPR2 protein, human